Preoperative Serum Prostate Specific Antigen Levels Between 2 and 22 Ng./Ml. Correlate Poorly With Post-Radical Prostatectomy Cancer Morphology: Prostate Specific Antigen Cure Rates Appear Constant Between 2 and 9 Ng./Ml.

Stamey, Thomas A.; Johnstone, Iain M.; McNeal, John E.; Lu, Arthur Y.; Yemoto, Cheryl

doi:10.1016/s0022-5347(05)65392-x

Cited by 152 publications

(94 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In populations regularly exposed to screening, levels of tPSA decrease significantly and eventually lose association with important disease characteristics. This is exemplified by recent reports from Stamey et al who found that tPSA did not predict treatment outcome after RP in men with tPSA from 2 to 9 ng/ml, 8 and a series of 1095 men with tPSA 10 ng/ml studied by Freedland et al who concluded that PSA was not an independent predictor of biochemical failure following RP in a multivariable model (p 5 0.09). 7 Hence, it is highly controversial whether tPSA remain as a significant predictor of treatment failure among men with a more narrow range of serum tPSA.…”

Section: Discussionmentioning

confidence: 82%

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

Steuber

Vickers

Haese

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Most models to predict biochemical recurrence (BCR) of prostate cancer use pretreatment serum prostate‐specific antigen (PSA), clinical stage and prostate biopsy Gleason grade. We investigated whether human glandular kallikrein 2 (hK2) and free prostate‐specific antigen (fPSA) measured in pretreatment serum enhance prediction. We retrospectively measured total PSA (tPSA), fPSA and hK2 in preoperative serum samples from 461 men with localized prostate cancer treated with radical prostatectomy between 1999 and 2001. We developed a regression model to predict BCR using preoperative tPSA, clinical stage and biopsy Gleason grade. We then compared the predictive accuracy of this “base” model with a model with fPSA and hK2 as additional predictors. BCR was observed in 90 patients (20%), including 48 patients with a pretreatment tPSA ≤ 14 ng/ml (13%), and 28 patients (10%) with a pretreatment tPSA ≤ 10 ng/ml. Overall, the predictive accuracy of the base model (bootstrap‐corrected concordance index of 0.813) was not improved after the addition of fPSA or hK2 (0.818). However, for men with moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), addition of fPSA and hK2 data increased predictive accuracy (from a base model concordance index of 0.756–0.815, p = 0.005). The improvement in accuracy was not sensitive to the threshold for “moderately elevated” PSA. For patients with a moderate tPSA‐elevation (tPSA ≤ 10 ng/ml), which closely corresponds to concurrent disease demographics, BCR‐prediction was enhanced when fPSA and hK2 were added to the conventional model. Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR. © 2005 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 82%

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

Steuber

Vickers

Haese

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Changes in the epidemiology of PCa have strongly limited the correlation between total PSA and the stage of PCa. [8][9][10] PSA can no longer be considered as a classical tumor marker whose levels are directly correlated with increasing stage of the disease. Moreover, the relationship with tumor grade remains unclear since it has been suggested that total PSA expression decreases with higher Gleason scores.…”

Section: Introductionmentioning

confidence: 99%

New circulating biomarkers for prostate cancer

Bensalah

Lotan

Karam

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…Screening for prostate speciWc antigen (PSA) in asymptomatic populations has increased the detection rate of prostate cancer as well as the number of surgical and radiotherapeutic treatments. Recently, the use of PSA as a diagnostic marker has come to be discussed (Stamey et al 2002). An elevated level of serum PSA not only detects aggressive malignancy but it is also associated with benign prostate hyperplasia (BPH) and with mildly aggressive, slowly progressing, neoplasia.…”

Section: Introductionmentioning

confidence: 99%

New experimental markers for early detection of high-risk prostate cancer: role of cell–cell adhesion and cell migration

Mól

Geldof

Meijer

et al. 2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Today's treatment and diagnosis of prostate cancer still exhibit major limitations. The search for new and additional prognostic markers is therefore still an actual Weld of interest. Potential markers involved in numerous biological processes in the tumor cell have been investigated intensively. For therapeutic interventions it is important to distinguish between harmless and aggressive disease in an early stage. Therefore the subject of this review is limited to markers associated with those functional processes, which discriminate early stage aggressive, metastatic cancer from harmless disease. Important processes in this respect are: altered cell adhesion and cellular migration. E-cadherin, N-cadherin, -catenin, integrins, focal adhesion kinase, connexins and matrix metalloproteinases all appear promising biological markers associated with the early stage metastatic process in prostate cancer. Here we discuss their potential to become valid biological markers based on literature data. Thus far, none of these markers proved to be a valid individual marker by itself due to prostate cancer heterogeneity and transient expression. Analyzing a combination of the potential markers discussed in this review is expected to be a better approach toward discriminating high-from low-risk tumors in an early stage of prostate cancer.

show abstract

Preoperative Serum Prostate Specific Antigen Levels Between 2 and 22 Ng./Ml. Correlate Poorly With Post-Radical Prostatectomy Cancer Morphology: Prostate Specific Antigen Cure Rates Appear Constant Between 2 and 9 Ng./Ml.

Cited by 152 publications

References 36 publications

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum

New circulating biomarkers for prostate cancer

New experimental markers for early detection of high-risk prostate cancer: role of cell–cell adhesion and cell migration

Contact Info

Product

Resources

About